QIAGEN And GENCURIX Partners To Develop Oncology Assays For Use On QIAcuityDx Platform, Digital PCR System Designed For Clinical Diagnostics

Author: Benzinga Newsdesk | June 18, 2025 04:06pm

• GENCURIX partnership marks launch of new QIAcuityDx Partnering Program for third-party in vitro diagnostic (IVD) assay development
• GENCURIX signs as inaugural partner to develop multiplex oncology assays for tissue and liquid biopsies
• Partnership aims to broaden adoption of QIAcuityDx Four platform offering clinical diagnostic laboratories a range of clinical oncology assays

QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) and GENCURIX, Inc. (KOSDAQ: 229000) today announced a new partnership to develop oncology assays for use on the QIAcuityDx platform, a high-performance digital PCR system designed for clinical diagnostics.

GENCURIX is the first development partner under QIAGEN's QIAcuityDx Partnering Program. This important advancement marks a significant step towards establishing a broad menu of in vitro diagnostic (IVD) assays on the QIAcuityDx Four platform, increasing access to digital PCR diagnostics.

The new partnership combines QIAGEN's QIAcuityDx digital PCR platform to advance sensitive, cost-effective oncology diagnostics with GENCURIX's expertise in multiplex assay development. The aim is to enable the creation of oncology IVD assays for both tissue and liquid biopsy applications, with flexible commercialization options and global reach through QIAGEN's Partnering Program.

Posted In: QGEN